Bret Christensen is a seasoned leader recognized for his exceptional ability to launch innovative solutions, penetrate markets and effectively scale businesses. With over two decades of experience in the healthcare sector, a specialized focus on women’s health and a comprehensive understanding of the broader healthcare landscape, Bret has consistently proven his ability to elevate emerging solutions into market share leaders, solidifying his reputation as a catalyst for growth and success.
Over the course of his distinguished career, Bret has held strategic commercial and general management leadership roles at Hologic (NASDAQ: HOLX), Myriad Genetics (NASDAQ: MYGN) and Insulet (NASDAQ: PODD), where he played a central role in revolutionizing treatments in women’s health care, oncology and diabetes, respectively. His strategic leadership drove significant revenue growth, achieved product commercialization success and advanced groundbreaking therapies that have redefined standards of care.
Bret’s expertise spans diagnostics, therapeutics and medical devices, positioning him as the ideal leader to accelerate Biote to its next level of growth. With a rare blend of business acumen and deep industry insight, he is uniquely equipped to drive Biote’s continued success as a leading educator in hormone optimization and therapeutic wellness while expanding its market presence and reach.
Bret holds a Bachelor of Science from Utah Valley University, a Masters of Business Administration from the University of Utah, David Eccles School of Business and several executive certifications from the University of Chicago Booth School of Business.
